|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Osteosarcoma | |||||
| 2 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Bone Tissue | |||||
| Neoplasms, Connective and Soft Tissue | |||||
| Neoplasms, Connective Tissue | |||||
| Sarcoma | |||||
| 3 | Interventions listed in this trial | ||||
| SLIT Cisplatin | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Cisplatin | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Transave | |||||